{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:21:46Z","timestamp":1785392506317,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001791","name":"Griffith University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001791","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ejphar.2020.173831","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T22:46:21Z","timestamp":1608677181000},"page":"173831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Quinazoline alpha-adrenoreceptor blockers as an adjunct cancer treatment: From bench to bedside"],"prefix":"10.1016","volume":"893","author":[{"given":"Liam","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5494-8751","authenticated-orcid":false,"given":"David","family":"Christie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Dare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nijole","family":"Bernaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russ","family":"Chess-Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3118-3084","authenticated-orcid":false,"given":"Catherine","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra","family":"Anoopkumar-Dukie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2020.173831_bib1","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.21037\/tcr.2019.09.03","article-title":"Prazosin inhibits the growth and mobility of osteosarcoma cells","volume":"8","author":"An","year":"2019","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.ejphar.2020.173831_bib2","first-page":"1617","article-title":"Doxazosin induces apoptosis in LNCaP prostate cancer cell line through DNA binding and DNA-dependent protein kinase down-regulation","volume":"27","author":"Arencibia","year":"2005","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejphar.2020.173831_bib3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.15252\/emmm.201505421","article-title":"The anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKC \u03b4-dependent inhibition of the AKT pathway","volume":"8","author":"Assad Kahn","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejphar.2020.173831_bib4","first-page":"597","article-title":"Quinazoline-derived \u03b11-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action","volume":"62","author":"Benning","year":"2002","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejphar.2020.173831_bib5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1046\/j.1464-410x.2000.00607.x","article-title":"Doxazosin: a new cytotoxic agent for prostate cancer?","volume":"85","author":"Cal","year":"2000","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2020.173831_bib6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1517\/14656566.3.2.167","article-title":"The use of \u03b1-adrenoceptor antagonists in lower urinary tract disease","volume":"3","author":"Chess-Williams","year":"2002","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2020.173831_bib7","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2020.173831_bib8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.neuroscience.2019.02.005","article-title":"Dual effect of doxazosin: anticancer activity on SH-SY5Y neuroblastoma cells and neuroprotection on an in vitro model of alzheimer's disease","volume":"404","author":"Coelho","year":"2019","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2020.173831_bib9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00428-005-1264-9","article-title":"NF-\u03baB in development and progression of human cancer","volume":"446","author":"Dolcet","year":"2005","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ejphar.2020.173831_bib10","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1210\/me.2004-0471","article-title":"\u03b11-adrenergic receptor antagonists: novel therapy for pituitary adenomas","volume":"19","author":"Fernando","year":"2005","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.ejphar.2020.173831_bib11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/pros.23167","article-title":"Relative cytotoxic potencies and cell death mechanisms of \u03b11 -adrenoceptor antagonists in prostate cancer cell lines","volume":"76","author":"Forbes","year":"2016","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2020.173831_bib12","first-page":"31","article-title":"The anti-hypertensive drug prazosin induces apoptosis in the medullary thyroid carcinoma cell line TT","volume":"35","author":"Fuchs","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejphar.2020.173831_bib13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00277-009-0704-z","article-title":"The \u03b11-adrenergic receptor antagonists, benoxathian and prazosin, induce apoptosis and a switch towards megakaryocytic differentiation in human erythroleukemia cells","volume":"88","author":"Fuchs","year":"2009","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejphar.2020.173831_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.tox.2015.09.008","article-title":"The cytotoxicity of the \u03b11-adrenoceptor antagonist prazosin is linked to an endocytotic mechanism equivalent to transport-P","volume":"338","author":"Fuchs","year":"2015","journal-title":"Toxicology"},{"key":"10.1016\/j.ejphar.2020.173831_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154612","article-title":"Phosphatidylinositol 3-Kinase\/AKT pathway inhibition by doxazosin promotes glioblastoma cells death, upregulation of p53 and triggers low neurotoxicity","volume":"11","author":"Gaelzer","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2020.173831_bib16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1745-7254.2008.00780.x","article-title":"Involvement of transcription factor activator protein-2\u03b1 in doxazosin-induced HeLa cell apoptosis","volume":"29","author":"Gan","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2020.173831_bib17","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1158\/0008-5472.CAN-05-2039","article-title":"Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway","volume":"66","author":"Garrison","year":"2006","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejphar.2020.173831_bib18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.tips.2013.06.005","article-title":"Cancer drug discovery by repurposing: teaching new tricks to old dogs","volume":"34","author":"Gupta","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2020.173831_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/ijc.20550","article-title":"Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer","volume":"113","author":"Han","year":"2005","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.ejphar.2020.173831_bib20","doi-asserted-by":"crossref","first-page":"8191","DOI":"10.1038\/s41598-020-65238-z","article-title":"A Pilot retrospective analysis of alpha-blockers on recurrence in men with localised prostate cancer treated with radiotherapy","volume":"10","author":"Hart","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2020.173831_bib21","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1097\/00005392-199805000-00041","article-title":"Effects of alprostadil and prazosin on motility, viability and membrane integrity of human sperm","volume":"159","author":"Hellstrom","year":"1998","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2020.173831_bib22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/00005344-199806000-00006","article-title":"Doxazosin inhibits proliferation and migration of human vascular smooth-muscle cells independent of \u03b11-adrenergic receptor antagonism","volume":"31","author":"Hu","year":"1998","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173831_bib23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2007.10.002","article-title":"The \u03b11-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-\u03baB signalling to induce breast cancer cell apoptosis","volume":"44","author":"Hui","year":"2008","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.ejphar.2020.173831_bib24","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1158\/1940-6207.CAPR-13-0095","article-title":"Oral naftopidil suppresses human renal-cell carcinoma by inducing G1 cell-cycle arrest in tumor and vascular endothelial cells","volume":"6","author":"Iwamoto","year":"2013","journal-title":"Canc. Prev. Res."},{"key":"10.1016\/j.ejphar.2020.173831_bib25","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.18.1.621","article-title":"Phosphorylation meets ubiquitination: the control of NF-\u03baB activity","volume":"18","author":"Karin","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2020.173831_bib26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biopha.2017.07.048","article-title":"Doxazosin nanoencapsulation improves its in vitro antiproliferative and anticlonogenic effects on breast cancer cells","volume":"94","author":"Krai","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2020.173831_bib27","first-page":"4550","article-title":"Suppression of human prostate cancer cell growth by \u03b11-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis","volume":"60","author":"Kyprianou","year":"2000","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejphar.2020.173831_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/1097-0045(2000)45:9+<42::AID-PROS9>3.0.CO;2-U","article-title":"Effects of alpha1-adrenoceptor (\u03b11-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease","volume":"9","author":"Kyprianou","year":"2000","journal-title":"Prostate Suppl."},{"key":"10.1016\/j.ejphar.2020.173831_bib29","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/S0022-5347(01)63162-8","article-title":"Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia","volume":"159","author":"Kyprianou","year":"1998","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2020.173831_bib30","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/pros.21313","article-title":"Anti-angiogenic effects and mechanism of prazosin","volume":"71","author":"Liao","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.ejphar.2020.173831_bib31","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1593\/neo.07475","article-title":"Prazosin displays anticancer activity against human prostate cancers: targeting DNA and cell cycle","volume":"9","author":"Lin","year":"2007","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejphar.2020.173831_bib32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejmech.2017.05.003","article-title":"Quinazoline based \u03b11-adrenoreceptor antagonists with potent antiproliferative activity in human prostate cancer cell lines","volume":"136","author":"Maestri","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2020.173831_bib33","first-page":"887","article-title":"Naftopidil induces apoptosis in malignant mesothelioma cell lines independently of \u03b11-adrenoceptor blocking","volume":"33","author":"Masachika","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejphar.2020.173831_bib34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.healthpol.2010.12.002","article-title":"The cost of drug development: a systematic review","volume":"100","author":"Morgan","year":"2011","journal-title":"Health Pol."},{"key":"10.1016\/j.ejphar.2020.173831_bib35","doi-asserted-by":"crossref","first-page":"470","DOI":"10.18632\/genesandcancer.37","article-title":"The antihypertension drug doxazosin suppresses JAK\/STATs phosphorylation and enhances the effects of IFN-\u03b1\/\u03b3-induced apoptosis","volume":"5","author":"Park","year":"2014","journal-title":"Genes Can."},{"key":"10.1016\/j.ejphar.2020.173831_bib36","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/sj.bjc.6600961","article-title":"Quinazoline-based \u03b1 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I \u03ba B \u03b1 induction","volume":"88","author":"Partin","year":"2003","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.ejphar.2020.173831_bib37","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1158\/0008-5472.CAN-07-5155","article-title":"Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271","volume":"68","author":"Roberts","year":"2008","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejphar.2020.173831_bib38","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.eururo.2010.12.038","article-title":"Anoikis disruption of focal adhesion-Akt signaling impairs renal cell carcinoma","volume":"59","author":"Sakamoto","year":"2011","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2020.173831_bib39","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0092-8674(00)80430-4","article-title":"Caspases: intracellular signaling by proteolysis","volume":"91","author":"Salvesen","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2020.173831_bib40","first-page":"1","article-title":"Quinazoline marketed drugs - a review","volume":"1","author":"Selvam","year":"2011","journal-title":"Res. Pharm."},{"key":"10.1016\/j.ejphar.2020.173831_bib41","first-page":"4281","article-title":"Growth inhibitory effect of doxazosin on prostate and bladder cancer cells. Is the serotonin receptor pathway involved?","volume":"25","author":"Siddiqui","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejphar.2020.173831_bib42","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","article-title":"Drug repurposing in cancer","volume":"124","author":"Sleire","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2020.173831_bib43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000488713","article-title":"Prazosin but not tamsulosin sensitises PC-3 and LNCaP prostate cancer cells to docetaxel","volume":"102","author":"Spencer","year":"2018","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejphar.2020.173831_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088164","article-title":"HERG K+ channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells","volume":"9","author":"Staudacher","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2020.173831_bib46","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3727\/096504009789745601","article-title":"Effects of \u03b1-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport","volume":"17","author":"Takara","year":"2009","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ejphar.2020.173831_bib47","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1126\/science.281.5381.1312","article-title":"Caspases: enemies within","volume":"281","author":"Thornberry","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2020.173831_bib48","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.bcp.2006.08.011","article-title":"Focal adhesion kinase: a potential target in cancer therapy","volume":"73","author":"van Nimwegen","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2020.173831_bib49","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00240-003-0365-7","article-title":"Induction of anoikis by doxazosin in prostate cancer cells is associated with activation of caspase-3 and a reduction of focal adhesion kinase","volume":"32","author":"Walden","year":"2004","journal-title":"Urol. Res."},{"key":"10.1016\/j.ejphar.2020.173831_bib50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10555-008-9165-4","article-title":"Signal transduction by focal adhesion kinase in cancer","volume":"28","author":"Zhao","year":"2009","journal-title":"Canc. Metastasis Rev."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920309365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299920309365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:43:52Z","timestamp":1757976232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299920309365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":49,"alternative-id":["S0014299920309365"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173831","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quinazoline alpha-adrenoreceptor blockers as an adjunct cancer treatment: From bench to bedside","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2020.173831","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173831"}}